Medical Information Notice: This article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified clinician for your personal situation.

Breast cancer is a malignant tumor that develops in the cells of the breast, typically in the ducts** (known as ductal carcinoma) or lobules (known as lobular carcinoma). **It is the most common cancer worldwide and affects both women and men, although it is rare in men.

Types of Breast Cancer:

  • Non-Invasive (In Situ):
    • Ductal Carcinoma in Situ (DCIS): Abnormal cells in milk ducts (pre-cancer).
    • Lobular Carcinoma in Situ (LCIS): Not true cancer, but increases future risk.
  • Invasive:
    • Invasive Ductal Carcinoma (IDC): ~80% of cases; spreads beyond ducts.
    • Invasive Lobular Carcinoma (ILC): ~10%; starts in lobules.
    • Triple-Negative Breast Cancer (TNBC): Aggressive; lacks ER/PR/HER2 receptors.
    • HER2-Positive Breast Cancer: Overproduces HER2 protein (faster growth).
    • Inflammatory Breast Cancer (IBC): Rare, aggressive; causes red/swollen breast.
  • Special Subtypes:
    • Paget’s disease of the breast, Phyllodes tumor, Angiosarcoma.

Common Symptoms:

  • New lump in breast/armpit.
  • Breast swelling, dimpling, or skin irritation.
  • Nipple retraction/discharge (non-milk).
  • Red/flaky breast/nipple skin.
  • Unexplained breast pain.
    Note: Some cancers show no symptoms, highlighting the need for screening.

Risk Factors:

  • Gender: 99% of cases occur in women.
  • Age: Risk ↑ after age 50.
  • Genetics: BRCA1/BRCA2 mutations (5–10% of cases).
  • Hormonal: Early menstruation, late menopause, hormone therapy.
  • Lifestyle: Alcohol, obesity, physical inactivity.
  • Other: Dense breasts, radiation exposure, family history.

Diagnosis & Staging:

  • Screening:
    • Mammography (primary tool for women 40+).
    • Ultrasound/MRI (for dense breasts or high risk).
  • Diagnostic Tests:
    • Biopsy (core needle/FNA to confirm cancer).
    • Receptor Testing: ER/PR/HER2 status.
  • Staging (TNM System):
    • Stage 0: DCIS/LCIS (non-invasive).
    • Stages I–II: Early/localized.
    • Stage III: Spread to lymph nodes.
    • Stage IV: Metastatic (spread to bones/lungs/liver).

Treatment Options

  • Surgery:
    • Lumpectomy (tumor removal) or Mastectomy (breast removal).
    • Lymph node removal (sentinel/axillary).
  • Radiation Therapy: Targets residual cancer cells post-surgery.
  • Systemic Therapies:
    • Chemotherapy (for aggressive/high-stage cancers).
    • Hormone Therapy (for ER/PR+ cancers; e.g., tamoxifen).
    • Targeted Therapy (e.g., trastuzumab for HER2+).
    • Immunotherapy (for TNBC expressing PD-L1).
  • Palliative Care: For advanced/metastatic cases.

Prevention & Early Detection:

  • Screening: Regular mammograms (start age 40–50, per guidelines).
  • Lifestyle: Limit alcohol, maintain weight, exercise, and avoid smoking.
  • Genetic Counseling: If a BRCA mutation or a strong family history.
  • Prophylactic Surgery: Considered for very high-risk patients.

Frequently Asked Questions (FAQ)

Q1: Who can get breast cancer?
Breast cancer predominantly affects women and is the most common cancer worldwide. However, men can also develop breast cancer, though it accounts for less than 1% of all cases. Risk increases with age, family history, hormonal factors, and certain gene mutations.

Q2: What is the role of BRCA1 and BRCA2 gene mutations?
BRCA1 and BRCA2 are tumor-suppressor genes. Inherited mutations in these genes significantly increase the lifetime risk of developing breast cancer (up to 70–80%) and ovarian cancer. People with a strong family history or known mutations are encouraged to seek genetic counseling for personalized risk assessment.

Q3: How often should I get a mammogram?
Guidelines vary by organization, but most recommend starting at age 40–50. High-risk individuals (BRCA carriers, strong family history, or prior chest radiation) may be advised to start earlier and to supplement mammograms with breast MRI. Discuss the best schedule with your healthcare provider.

Q4: What is triple-negative breast cancer (TNBC)?
TNBC is a subtype that lacks estrogen receptors (ER), progesterone receptors (PR), and HER2 protein. Because it doesn't respond to hormone therapy or HER2-targeted drugs, treatment primarily relies on chemotherapy and immunotherapy. It is generally more aggressive but can respond well to chemotherapy.

Q5: Can breast cancer be prevented?
There is no guaranteed prevention, but risk can be reduced through regular screening (for early detection), limiting alcohol, maintaining a healthy weight, staying physically active, and avoiding long-term hormone replacement therapy. High-risk individuals may consider preventive medications (chemoprevention) or prophylactic surgery after thorough counseling.

Q6: What is the difference between a lumpectomy and a mastectomy?
A lumpectomy removes only the tumor and a margin of surrounding tissue, preserving most of the breast. A mastectomy removes the entire breast. Both are equally effective for many early-stage cancers when combined with appropriate additional treatment. The choice depends on tumor size, location, genetics, and patient preference.

Q7: What does it mean when breast cancer is "hormone receptor-positive"?
Hormone receptor-positive breast cancer has receptors for estrogen (ER+) and/or progesterone (PR+), meaning the cancer cells use these hormones to grow. This subtype is treated with hormone (endocrine) therapy such as tamoxifen or aromatase inhibitors, which block or reduce hormone supply to the cancer cells.

Medical Disclaimer

MediPulse publishes this content for patient education. It may not reflect the latest guideline changes in every jurisdiction. Do not delay seeking care because of something you read here.